Clinical Features and Prognosis of 188 Patients with Acute Myeloid Leukemia-M.
10.19746/j.cnki.issn.1009-2137.2019.05.002
- Author:
Jing-Jing WANG
1
;
Chao WANG
1
;
Xiao-Shuang YAN
1
;
Jin-Lan PAN
1
;
Ming-Qing ZHU
1
;
Jian-Nong CEN
1
;
Su-Ning CHEN
1
;
Dan-Dan LIU
2
Author Information
1. Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215006, Jiangsu Proince, China.
2. Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215006, Jiangsu Proince, China,E-mail: liudd_2006@126.com.
- Publication Type:Journal Article
- MeSH:
HLA-DR Antigens;
Humans;
Immunophenotyping;
Leukemia, Myeloid, Acute;
Middle Aged;
Mutation;
Prognosis;
Retrospective Studies
- From:
Journal of Experimental Hematology
2019;27(5):1360-1366
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To summarize the clinical characteristics of patients with acute myeloid leukemia-type M (AML-M) and analyze the factors affecting the prognosis.
METHODS:One hundred eighty-eight AML-M patients were retrospectively analyzed for the following parameters including peripheral blood, immune phenotypes, fusion genes and cytogenetics to explore their significance for the overall survival (OS) and progression-free survival (PFS). The prognostic factors were also analyzed.
RESULTS:Among 188 patients with AML-M, the chromosomal abnormality with t (8;21), normal chromosome and other abnormalities accounted for 37% (70/188), 41% (77/188) and 22% (41/188), respectively. For the immunopheno typing of M patients, the hematopoietic progenitor cell differentiation antigen CD117 (96.1%) were mainly expressed, CD34 (81.6%) and HLA-DR (55.9%), and myeloid-associated antigen of CD13 (90.5%) and CD33 (89.4%) were also highly expressed. There were lymphoid-associated antigens expressed in some patients, among which the positive expression rate of CD19 was highest (29.6%), and the next was CD7 (28.5%). The most common accompanied mutations was FLT3 mutation (30.2%). The univariate analysis showed that the patients at age＜50 years old, without extramedullary infiltration, with positive expression of CD19, NPM-1 (-), CEBPA double mutation(+), and HSCT were significant superior in OS and PFS (P＜0.05); the multivariate analysis showed that the patient at age＜50 years old, without extramedullary infiltration, with positive expression of CD19 and CEBPA double mutation (+) were significant superior in OS and PFS (P＜0.05). The analysis indicated that the Karytypes affected only OS (P＜0.05), while the NPM-1 gene mutation positive affected only PFS (P＜0.05). The univarate analysis of factors affecting the survival in 70 AML-M patients with t (8;21) abnormatity showed that the C-KIT gene mutation was a poor factor for OS and PFS.
CONCLUSION:The clinical characteristics are different between M patients with different karyotype, and prognostic analysis shows that the karytypes have an impact on overall survival; age, extramedullary infiltration, CD19 expression and CEBPA double mutation are also the main factors impacting the prognosis of patients.
